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                                        INTRODUCTION
Intravenous regional anaesthesia is a regional technique in which analgesia and 
muscle relaxation are produced by the injection of an adequate volume of local 
anaesthetic solution into a vein of an extremity with inflow and outflow of the blood 
prevented by proximally applied tourniquet. 
The  history  of  intravenous  regional  anaesthesia  had  begun  with 
August Bier, who described the technique in 1908. But in 1970 after a lapse 
of 62 years, the technique was modified and popularized by Holmes as “Bier 
Block” 
Lignocaine has been the drug most frequently used for intravenous 
regional anaesthesia, as it is the only drug approved for intravenous regional 
anaesthesia. Lignocaine is considered as a less toxic local anesthetic. It is 
used  intravenously  for  treating  ventricular  arrhythmias  in  the  dose 
of  1-2mg/kg  safely  and  also  used  for  attenuating  stress  response  to 
endotracheal intubation.
 However  in  intravenous  regional  anaesthesia  toxic  reactions  like 
convulsions, coma, cardio respiratory depression and cardiac arrest has been 
reported following its use. Toxicity may be due to leakage of the drug past 
the  tourniquet  after  the  injection  because  of  either  tourniquet  failure  or 
buildup of excessively high venous pressure distal to the tourniquet.
Intravenous regional anaesthesia has been limited by tourniquet pain 
and  inability  to  provide  postoperative  analgesia.  To  improve  quality  of 
intravenous  regional  anaesthesia  various  drugs  like  ketorolac,  morphine, 
meperidine,  tramadol,  fentanyl,  sufentanil  and  small  dose  of  muscle 
relaxants like pancuronium and atracurium have been added to lignocaine.
In our study it was decided to evaluate the efficacy of sufentanil 25µg 
or  tramadol  100mg added  to  0.5% lignocaine  in  reducing  sensory  block 
onset and recovery time, motor block onset and recovery time, duration of 
post  operative  analgesia,  tolerance  to  tourniquet  pain  and requirement  of 
postoperative analgesic drugs.   
AIM OF THE STUDY
The aim of the study is to evaluate the efficacy of 25µg sufentanil 
added to 0.5% lignocaine and 100mg tramadol added to 0.5% lignocaine in 
intravenous regional anaesthesia for hand surgeries. 
ANATOMY OF SUPERFICIAL VEINS OF UPPER LIMB
The venous supply of the upper limb is arranged in two planes, which 
are separated by superficial aponeurosis. The superficial venous system is 
used for intravenous regional anesthesia.
The  dorsal  digital  veins  converge  to  form three  dorsal  metacarpal 
veins that are interlinked to each other. The palmar digital veins drain into 
dense vascular network on the palmar face of the hand and also into dorsal 
digital  veins by way of intercapillary veins. Most of the superficial veins 
join to form two large veins, the cephalic vein and the basilic vein, which 
present  several  anatomic  variations.  An  accessory  cephalic  vein  is  often 
present.
The cephalic vein is the preaxial vein of the upper limb. It begins from 
the lateral end of the dorsal venous arch. The cephalic vein runs upward 
through the root of the anatomic snuff box, and winds around the lateral 
border  of  the  dorsal  forearm.  In  the  proximal  part  of  the  forearm,  the 
cephalic vein runs medially to run along the anterior aspect of the forearm. 
Here, several branches from palmar plexus of veins join it.
At the level of elbow, it runs between the tendons of brachioradialis 
and the biceps brachii, crosses the lateral cutaneous nerve of forearm and 
then runs along the lateral  border  of the biceps.  It  then pierces the deep 
fascia  at  the  lower  border  of  pectoralis  major  and  then  runs  in  the 
deltopectoral  groove  up  to  the  infraclavicular  fossa  where  it  pierces  the 
clavipectoral fascia and joins the axillary vein. 
The  accessory  cephalic  vein,  when  present  rises  from  a  venous 
network on the back of the forearm or from the lower part of cephalic vein. 
It joins the cephalic vein below the elbow or in front of the elbow. when 
main cephalic vein drains into the basilic vein, the accessory cephalic vein 
may follow the course of the former above the elbow.
The basilic vein is the postaxial vein of the upper limb and arises from 
the medial end of the dorsal venous arch a little below thumb. It runs upward 
along the back of the medial border of the forearm, winds around this border 
to reach the ventral aspect of cubital fossa and then runs along the medial 
aspect of the biceps brachii up to the middle of the arm, pierces the deep 
fascia and runs along the medial side of the brachial artery, up to the lower 
border of the teresmajor where it continues as axillary vein. About 2.5 cm 
above the medial  condyle  of  the humerus,  the basilic  rein  joined by the 
medial cubital vein. It is accompanied by the posterior branch of the medial 
cutaneous nerve of the forearm and the terminal part of the dorsal branch of 
the ulnar nerve. 
The superficial palmar venous network is drained by median vein of 
forearm, which runs along the anterior aspect of the forearm, in front of the 
elbow, it drains directly into basilic vein. 
ANATOMY OF NERVE 
Neurons in human central nervous system are in many different size 
and shapes. These cells have five to seven processes called dendrites that 
extend  outward  from  the  cell  body  and  arborize  extensively.  A  typical 
neuron also has a long fibrous axon that originates from a thickened area of 
cell body called as axon hillock. The first portion of the axon is called as 
initial segment. The axon divides into terminal branches ending in a number 
of synaptic knobs.  
The axons are wrapped by a sheath of myelin, a protein rich complex 
produced by schwann cells. The myelin sheath envelops the axon except at 
its  ending or  the nodes of Ranvier,  a  periodic 1-µm constriction that  are 
about 1mm apart. 
There  are  some  neurons  are  unmyelinated,  which  are  simply 
surrounded  by  schwann  cells  without  the  wrapping  of  schwann  cell 
membrane around the axon. 
PHYSIOLOGY OF NERVE CONDUCTION
ACTION POTENTIAL
The resting membrane potential of the nerve is about – 70 mV. If the 
axon is  stimulated and a  conducted  impulse occurs,  a  series  of  potential 
changes occurs, which is known as action potential.  
The first manifestation of approaching action potential is a beginning 
of depolarization of membrane. After initial 15mV of depolarization, the rate 
of depolarization increases, the point called as threshold. Thereafter rapidly 
reaches and overshoots to +35mV.It then reverses and falls rapidly towards 
resting level. The sharp rise and fall are spike potential of axon, and slower 
fall at the end of process is after depolarization. After reaching the previous 
resting  level,  there  is  prolonged  hyper  polarization  called  after-hyper 
polarization. During the phase of spike potential, the neuron is refractory to 
stimulation called as absolute refractory period. 
IONIC FLUXES DURING ACTION POTENTIAL
During action  potential,  there  is  opening of  Na+ channels  and Na+ 
enters into the nerve cell. The Na+ channels rapidly enter into a closed state 
called as inactivated state and then returning to resting state.
During repolarization there is opening of voltage gated K+ channels, 
and K+  moves out of cell. The net movement of positive charge out of the 
cell due to K+  efflux helps to complete the process of repolarization. The 
slow  return  of  K+  channels  to  closed  state  is  responsible  for  after  – 
repolarization. 
OPIOID RECEPTORS
The opioid receptors are classified as mu (µ), delta (δ) and kappa (κ) 
receptors.  These  receptors  are  belonging to  super  family  of  guanine  (G) 
protein coupled receptors.
µ receptors  or  morphine  preferring  receptors  are  principally 
responsible for supraspinal and spinal analgesia. Activation of subpopulation 
µ receptors  (µ1)  is  responsible  for  analgesia,  where  as  µ2 receptors  are 
responsible for hypoventilation, bradycardia and physical dependence. The 
beta  endorphins  are  endogenous  ligand  for  µ receptors.  The  exogenous 
ligands for these receptors are morphine, fentanyl, alfentanil, sufentanil and 
remifentanil.
   Endogenous agonists for kappa receptors are dynorphins. Activation 
of these receptors resulting in inhibition of neurotransmitter release via type 
N  calcium  channels.  Respiratory  depression  is  less  with  kappa  receptor 
although dysphoria and diuresis may occur.
Delta receptors respond to the endogenous ligands, encephalins and 
these receptors may serve to modulate the activity of µ receptors.
PERIPHERAL OPIOID RECEPTORS
Pain  can  be  effectively  diminished  by  various  endogenous 
mechanisms within  the  central  nervous  system.  One  region  where  these 
mechanisms have been well characterized is the dorsal horn of the spinal 
cord, in which impulses from peripheral nerves are modulated before they 
are transmitted centrally to evoke perception and response. Recent research 
has  shown  that,  in  addition  to  these mechanisms  in  the  central  nervous 
system,  intrinsic  modulation of  nociception  can  occur  at  the  peripheral 
terminals of afferent nerves. Specifically, the immune system can interact 
with peripheral sensory-nerve endings to inhibit pain
Notwithstanding the traditional view that opioid antinociception takes 
place exclusively  within  the  central  nervous  system,  there  are  peripheral 
opioid receptors that mediate analgesic effects when activated by exogenous 
opioid agonists applied locally. Such effects are particularly prominent in 
painful inflammatory conditions. The opioid receptors on peripheral sensory 
nerves are  up regulated during inflammation.  Their  endogenous ligands - 
opioid peptides -  are expressed by the resident  immune cells in inflamed 
peripheral tissue. Environmental stimuli and endogenous substances, such as 
corticotropin-releasing hormone and cytokines, can stimulate the release of 
these  opioid  peptides,  resulting in  local  analgesia.  Suppression  of  the 
immune system abolishes these effects. Thus,  it  is  likely that  endogenous 
opioid peptides can be secreted from immune cells, occupy opioid receptors 
on sensory nerves, and cause analgesia by inhibiting either the excitability of 
these nerves or the release of excitatory, proinflammatory neuropeptides.
Opioids bind to receptors on dorsal-root ganglia, the central terminals 
of primary afferent neurons, and peripheral sensory-nerve fibers and their 
terminals. The characteristics of these receptors are very similar to those in 
the brain. Dorsal-root ganglia contain messenger RNA (mRNA) for opioid 
receptors, and primary afferent nerves mediate the peripheral antinociceptive 
effects of opioid. 
Opioid agonists have easier access to neuronal opioid receptors during 
inflammation  because  inflammation  disrupts the  perineurium (normally  a 
rather impermeable sheath encasing peripheral-nerve fibers) and because the 
number of peripheral sensory-nerve terminals is increased in inflamed tissue, 
a phenomenon known as sprouting. In addition, previously inactive neuronal 
opioid receptors may become active in the inflammatory milieu.
Peripherally acting opioids would allow analgesia without central side 
effects,  such  as  dysphoria,  respiratory depression,  sedation,  nausea,  or 
addiction,  and  without  the side  effects  either  of  nonsteroidal  anti 
inflammatory  drugs  (e.g., renal  toxicity  and  gastric  bleeding)  or  of  local 
anesthetic drugs (motor- and autonomic-nerve blockade). Whether tolerance 
to the analgesic effects of peripherally active opioids develops is not known. 
The fact that peripheral opioid actions are particularly prominent in inflamed 
tissue  may  be  clinically  advantageous, considering  that  many  painful 
conditions,  sub  acute  or  chronic, are  associated  with  inflammation  (for 
example, trauma, postoperative pain, pain due to cancer, and arthritis).
PHARMACOLOGY
LIGNOCAINE
Lignocaine is  one of an amide group local anesthesia.  It  is  diethyl 
aminiacetyl 2, 6-xylidine hydrochloride monohydrate.
PHYSICAL PROPERTIES
Lignocaine is  a  weak base with pK value of  7.9.At the pH of 7.4 
lignocaine  has  25  % of  non  ionized  fraction.  It  has  the  protein  binding 
capacity of 70%.
MECHANISM OF ACTION
Lignocaine  prevents  transmission  of  nerve  impulse  by  inhibiting 
passage  of  sodium  ions  through  ion-selective  sodium  channels  in  nerve 
membrane. Lignocaine selectively binds to sodium channels in inactivated 
closed states and there by stabilizes these channels in this configuration and 
prevent their change to rested closed and activated - open states in response 
to nerve impulse.
METABOLISM
The  principal  metabolic  pathway  of  lignocaine  is  oxidative 
dealkylasion in liver to monoethyl glycine xylidide followed by hydrolysis 
to xylidide.  Approximately 75% of xylidide is excreted in the urine as 4 
hydroxy 2, 6- dimethylaniline.
SIDE EFFECTS
Apart  from  Na+ channels,  lignocaine  binds  many  other  targets 
including voltage-gated K+  and Ca2+ channels, K+ ATP channels, enzymer, 
NMDA  receptors  and  nicotinic  acetylcholine  receptors.  Binding  of 
lignocaine to these sites may contribute toxic side effects. 
CENTRAL NERVOUS SYSTEM TOXICITY
Lignocaine at low concentrations likely to produce numbness of the tongue and 
circumoral tissues. As plasma concentration increases restlessness, vertigo, tinnitus and 
difficulty in focusing may occur initially. Further increase in the concentration result in 
slurred speech, skeletal muscle twitching, drowsiness and seizures that due to selective 
depression of inhibitory cortical neurons leaving excitatory pathways unopposed.
CARDIOVASCUTLAR TOXICITY
Cardiovascular system is more resistant to toxic effect of lignocaine 
than central nervous system. At plasma concentration 5-10µg/ml, lignocaine 
may produce profound hypotension and direct myocardial depression.
TRAMADOL
Tramadol hydrochloride is a new centrally acting synthetic opioid. It 
possesses  opioid  agonist  properties  and  activates  mono  aminergic  spinal 
mechanism of  inhibition  of  pain.  The  analgesic  property  of  tramadol  is 
combined  with  low  respiratory  depressant  effect  and  low  dependence 
potential. 
Tramadol hydrochloride is (+, -) trans-2-dimethyl aminomethyl-1-m-
methoxyphenyl-cyclohexanol hydrochloride.
Molecular formula C16H25 O2NHCl
CHEMISTRY OF TRAMODAL
Tramadol is a synthetic 4-phenyl piperidine analogue of codeine. It 
has pure opioid agonistic property with no antagonistic property. Tramadol 
like  codeine  has  a  methyl  substitution  on  the  phenolic  moiety  of  the 
morphine  structure,  which  explains  its  relative  weak  affinity  for  opioid 
receptor.  It  has  selective  affinity  for  µ  receptors.  The  O-desmethyl 
metabolite  of  tramadol  has  2-4  times  analgesics  potency  of  the  parent 
compound and 4 to 200 times greater affinity for µ receptors than the parent 
compound.
MECHANISM OF ACTION
Tramadol  produces  its  anti  nociceptive  effect  by  two  different  but 
synergistic analgesic actions.
Opioid action: Tramadol is a µ opioid receptor agonist. However the
affinity for µ opioid receptor is 6000 fold less than morphine and 10 fold 
less than codeine. Tramadol acts only on µ1 thus it does not cause respiratory 
depression as an adverse effect.
Non-opioid action:  Tramadol inhibits the reuptake of serotonin 
and nor adrenaline in the descending spinal inhibitory pathway enhancing 
effectiveness  of  the  inhibitory  pathway.  These  neurotransmitters  in  the 
descending  pathways  enhance  the  analgesic  response  without  inducing 
adverse  effects  on  cardiovascular  and  respiratory  system.  Tramadol 
combines the mechanism of action of opioids and tricyclic antidepressants.
PHARMACOKINETICS
Tramadol is metabolized in the liver by two main metabolic pathways 
to  form  N  and  O  desmethylated  compounds  (Phase  I  reaction).  The  O 
desmethylated  metabolites  are  further  conjugated  (Phase  II  reactions).  A 
total of 11 metabolites have been identified, 5 from phase I reaction and 6 
from phase 11 reaction. Apart from O desmethyl tramadol M1 all the other 
metabolites are pharmacologically inactive. Production of M1  is dependent 
on the CYP2D6 isoenzyme of the cytochrome p450 enzyme system.
Tramadol and its metabolites are excreted primarily in the urine. The 
mean ± SD terminal elimination half lifes of tramadol and its metabolite M1 
are 6.3 ± 1.4 and 7.4 ± 1.4 hrs respectively in healthy young adults whether 
the drug is administered orally or intravenous. Hepatic impairment and renal 
insufficiency results in prolongation of elimination half lives of tramadol. 
Serum concentration after 100 mg intravenous of tramadol at 15 min and 2 
hrs are 613 and 409 µg/ml.
PHARMACODYNAMICS
Analgesic property
The  analgesic  activity  of  tramadol  hydrochloride  is  attributable  to 
both parent  drug and its M1 metabolite.  Serum tramadol concentration of 
100-300 µg/ml is required for analgesic activity. It is effective in treating 
acute pain like post operative pain, labour pain, ureteric colic, dental pain, 
acute myocardial infarction, angina, traumatic injuries and in chronic pain 
like cancer pain and osteoarthritis.
Respiratory System
Minimal changes in respiratory rate and tidal volume when compared 
to morphine and no respiratory depression.
Cardiovascular System
The healthy volunteers intravenous bolus doses of tramadol 100 mg 
causes an increase in heart rate of 7-10 beats/min and increase in systolic 
and diastolic blood pressure of 6 and 14 mm Hg respectively over a period 
of 5-8 minutes after injection. These changes are returned to normal values 
by 15 minutes.
Gastrointestinal System
Tramadol may produce nausea, vomiting constipation and dry mouth. 
However  these adverse effects  are particularly  likely to occur after  rapid 
intravenous injection. To prevent these effects intravenous tramadol is best 
administered slowly.
Physical Dependence
Unlike morphine or pethidine tramadol has least addiction potential.
OTHER EFFECTS
Tramadol 1 mg/kg intravenously reduces post anesthetic and spinal 
shivering.  It  has dose dependent  antitussive effects.Tramadol has a weak 
antioedema action. 
DOSAGE AND ADMINISTRATION
Tramadol can be administered through oral, parenteral, epidural and 
intrathecal  routes.  The  dose  is  1-2  mg/kg  whether  administered 
intramuscular, intravenous, oral or epidural. Maximum recommended dose 
is 400 mg/day.
ADVERSE EFFECTS
Tramadol  causes  non-specific  irritation,  sedation  (very  mild  when 
compared to other opioids), headache and seizure. 
Tramadol may produce nausea, vomiting, constipation and change in 
appetite.  It  will cause tachycardia, dry mouth, sweating, and allergic skin 
reaction.
SUFENTANIL
Sufentanil  is  a  phenylpiperidine series of synthetic opioid which is 
thienyl analogue of fentanyl.
PHYSICAL PROPERTIES
The pKa of sufentanil is 8.0. The percentage of nonionised fraction at 
pH 7.4 is 20%. The protein binding capacity  of  sufentanil  is  93%.  It 
primarily  binds  to  alpha 1 acid glycoprotein.  The partition coefficient  of 
sufentanil is 1,727.
Volume  of  distribution  of  sufentanil  is  123litres.Clearance  of 
sufentanil is 900ml/min. the elimination half-life is 2.2- 4.6 hours. Context 
sensitive half-life is 30 minutes
DOSE
Sufentanil given in the dose of 0.1-0.4  µg /kg for intravenous route. 
For  intrathecal  administration  sufentanil  given  in  the  dose  0.01-0.06  µg 
single dose.
METABOLISM 
Sufentanil has high hepatic extraction ratio. It undergoes significant 
first pass pulmonary uptake after rapid intravenous injection.
Sufentanil  rapidly  metabolized  by  N-dealkylasion  at  piperidine 
nitrogen and by o-demethylation. Less than 1% of an administered dose of 
sufentanil appeared unchanged in the urine.
PHARMACOGICAL PROPERTIES
 ANALGESIC PROPERTY
The analgesic effects of sufentanil are similar to morphine. Sufentanil 
is approximately 1000 times more potent than morphine.  Sufentanil is far 
more  lipid  soluble  than  morphine,  thus  the  risk  of  delayed  respiratory 
depression from rostral spread of intrathecal opioid is greatly   reduced.
The  peak  analgesic  effect  of  sufentanil  after  intravenous 
administration is 5min. Recovery from analgesic effects also occurs more 
quickly.
OTHER CNS EFFECTS
As with other µ opioids nausea, vomiting and itching can be observed 
with sufentanil.
Muscle  rigidity  is  more common after  administration of  sufentanil. 
This effect  is  felt  to be centrally  mediated.  Rigidity  can be mitigated by 
avoiding bolus dosing,  slower administration of  boluses and pretreatment 
with  a  non-opioid  anesthetic  induction  agent.  Respiratory  depression  is 
similar to other opioid but onset is more rapid and short duration.
CARDIOVASCULAR EFFECTS
Sufentanil decreases heart rate and mildly decreases blood pressure. 
But in general provide a marked degree of cardiovascular stability. Direct 
depressant effects on the myocardium are minimal.
.
PHARMACOKINETIC ASPECTS OF INTRAVENOUS REGIONAL 
ANAESTHESIA
The exact mechanism of analgesia and muscle paralysis produced by 
this technique is not clear. It has been suggested that large venous channels 
that surround the nerve provide access for the drug to the vascular channels 
in the core of nerves. 
SITE OF ACTION
The site and mode of action of the drug is still controversial. The three 
most probable sites of action are
a. The sensory nerve endings 
b. The neuromuscular junction 
c. The nerve trunks.
According to Adams at al (1964) the anaesthetic solution is for more 
effective when placed into the isolated vascular tree rather than in the tissues 
at random. By this method the capillaries perform an important function in 
the production of anesthesia by transporting the lignocaine very effectively 
to both large and small nerves. This would explain the rapid decrease in the 
large nerve conduction speed as well as peripheral anaesthesia which first 
appears close to the point of injection. Since lignocaine is effectively shut 
off  from  the  general  circulation  it  does  not  reach  the  liver  and  is  not 
destroyed. There fore gives anaesthesia as long as it is trapped in the arm. 
On release of tourniquet the remaining solution seems to be very rapidly 
flushed out of extremity.
The pharmacokinetic aspects of intravenous regional anaesthesia have 
been described by  Tucker & Boas (1971). They described that after cuff 
release the peak plasma concentration of lignocaine were 20-80% less than 
when same dose of lignocaine injected by direct intravenous route. The peak 
level  achieved  was  inversely  proportional  to  total  time of  the  tourniquet 
applied. 
C.J. Evans et al (1974) studied the duration of residual anaesthesia 
following release of tourniquet after intravenous regional anaesthesia. They 
found that  the duration of block was related to duration of  action of  the 
drugs  when  used  clinically.  With  intravenous  regional  anaesthesia,  the 
ability  of  the drug to  remain in the nerve in  sufficient  quantity  to  cause 
blockade  of  the  neural  transmission  is  important  in  regard  to  residual 
anesthesia. As the drug reaches the nerve tissue by vascular channels and not 
by penetrating the nerve sheath,  the duration of  residual  anaesthesia  was 
found to be longest with bupivacaine and shortest with prilocaine. Both the 
safety and efficacy of the procedure depend on the interruption of the blood 
flow to the involved limb. 
MATERIALS AND METHODS
This study was conducted in patients  undergoing hand surgeries in 
Thanjavur  medical  college  hospital.  The  total  number  of  patients  was 
seventy five. After getting institutional ethics committee approval and after 
explaining the procedure in detail,  informed consent obtained from every 
patient. The patients were assigned in following groups.
Group L: Patients in this group received 40ml of 0.5% lignocaine 
Group LS: Patients in this group received 40ml of 0.5% lignocaine and 25µg 
sufentanil added. 
Group LT: Patients in this group received 40ml of 0.5% lignocaine and 100mg 
tramadol added.
SELECTION OF PATIENTS
The patients selected for this study were of ASA I and II, undergoing elective or 
emergency hand surgeries.
EXCLUSION CRITERIA
Patient with history of any cardiovascular, respiratory or central 
nervous system disorders. Patients with haematological disorders like sickle cell anemia, 
thalasemia. Patients of known hypersensitivity to lignocaine and patients with anticipated 
difficult airway were excluded from study.
PREANESTHETIC ASSESSMENT
Physical status of all patients was preanaesthetically assessed. A thorough airway 
assessment done. The following investigations were done on the patients.
INVESTIGATIONS
. Hemoglobin
. Urine analysis
. Blood sugar
. Blood urea & serum creatinine
. Chest x-ray
. Electro cardiogram
RESUSCITATIVE MEASURES
The following resuscitative drugs and equipments were kept ready to meet any 
emergency.
.  Boyle’s apparatus 
.  Laryngoscope with appropriate size blade 
.  Endotracheal tube of various sizes and connectors
.  Suction apparatus
. Drugs like anticonvulsants, antihistamines, vasopressors, steroids and 
bronchodilators. 
PROCEDURE
The patients were shifted into the operation theatre. The pulseoximeter,non-
invasive blood pressure monitor and electrocardiographic monitor were connected to 
patient. All vital parameters were recorded.    
A separate intravenous line was started in the non-operative limb. A vein in 
dorsum of the hand of the operative limb was cannulated with 22G intravenous cannula. 
If the dorsum of the hand involved in the surgery a vein higher up in the forearm was 
chosen. It was firmly, fixed, flushed with normal saline and stoppered.
Exsanguination was accomplished by elevation of limbs for 5 minutes followed 
by use of esmarch bandage from fingertip to arm. In subjects where application of 
esmarch bandage was not feasible, emptying of veins was facilitated with compression of 
axillary artery while limb elevated.
At the proximal end of esmarch bandage the first tourniquet was applied around 
the upper part of the arm over the cotton wool padding. Then the tourniquet was inflated 
to 250 mmHg. Circulatory isolation of the arm was verified by inspection, absence of 
radial pulse and loss of pulseoximeter tracing of the ipsilateral index finger. Then 40ml of 
local anaesthesia solution was injected through the cannula at a rate of 1ml/ second. After 
the injection of solution the intravenous cannula was removed.
After ensuring complete analgesia below first tourniquet, the second tourniquet 
was applied distal to the first tourniquet and inflated to 250mmHg. The first tourniquet 
was removed. The patient was observed for any local anaesthetics toxic manifestations 
after release of the first tourniquet. The following parameters were recorded.
Time of onset of sensory block:
The time elapsed from injection of study drug to sensory block achieved in all 
dermatomes. This was checked by pinprick every minute till the onset.
Time of onset of motor block:
The time elapsed from injection of study drug to inability  of voluntary 
movements. This was checked by asking the patient to flex elbow and hand every 
minute till the onset.
Time of Sensory block recovery:
The time elapsed from tourniquet deflation to recovery of pain in all dermatomes.
Time of motor block recovery:
The time elapsed from tourniquet deflation to ability of voluntary movement  
Assessment of tourniquet pain:
Assessment of tourniquet pain was made on the basis of visual analogue scale 
(VAS), where O = no pain and 10 = worst imaginable pain. Tourniquet pain was 
measured after tourniquet application and 5,10,20,40 minutes after injection of 
study drug.
Duration of postoperative pain relief:  
The time elapsed from tourniquet release to the first dose of analgesic 
Inj.diclofenac
Total dose of analgesic: 
Total dose of analgesic Inj.diclofenac in mg for the first 24 hours post operatively. 
Vital parameters like blood pressure, pulse rate were recorded intra operatively.  
At the end of surgery, tourniquet deflation was performed using cyclic deflation 
method that is the tourniquet was deflated for 3 times for 10 seconds separated by 1 
minute interval of reinflation. The patients were carefully observed for possible side 
effects during and after the release of tourniquet. The tourniquet was not deflated before 
30 minutes and was not inflated for more than 90 minutes. The total duration of 
tourniquet and surgery was noted. The patients were followed up for 24 hours post 
operatively.    
OSERVATION AND RESULTS
Table 1
Age distribution 
Age distribution 
in years Group L Group LT Group LS
< 20
21-30
31-40
41-50
> 51
3
6
9
5
2
3
12
1
7
2
3
16
3
3
0
Total 25 25 25
Mean age in years in group L is 35.2
Mean age in years in group LT is 34.4
Mean age in years in group L Sis 29.3
Table 2
Sex distribution
Sex Group L Group LT
Group LS
Male
Female
19
6
20
5
20
5
Total 25 25 25
Table 3
Weight distribution
Weight in kgs Group L Group LT
Group LS
< 50
51-60
> 60
8
14
3
6
12
11
9
11
5
Total 25 25 25
Mean weight in group L is 52.5
Mean weight in group LT is 57.9
Mean weight in group LS is 53.8
Table 4
Time of onset of sensory block 
Time of onset of 
sensory block in 
minutes
Group L Group LT Group LS
< 3 min
3-5 min
6-7min
>7
0
13
12
0
0
21
4
0
1
24
0
0
Meantime and standard deviation of sensory block onset in group L is 
5.6+0.93
Meantime and standard deviation of sensory block onset in group LT is 
4.8+0.79 and p value is <0.05(statistically significant)
Meantime and standard deviation of sensory block onset in group LS is 
3.6+0.61and p value is <0.05(statistically significant)
The mean time required for onset of sensory block on group LS was 
less than group L and group LT. The mean time required for onset of 
sensory block on group LT was less than group L. 
Table 5
Time of onset of motor block
Time of onset of 
motor block in 
minutes
Group L Group LT Group LS
< 3
3-5
6-8
8-10
>10
0
0
8
11
6
0
0
3
21
1
0
13
8
4
0
Meantime and standard deviation of motor block onset in group L is 
9.28+1.68
Meantime and standard deviation of motor block onset in group LT is 
8.88+1.12 and p value is >0.05(statistically not significant).
Meantime and standard deviation of motor block onset in group LS is 
6.31+0.3 and the p value is <0.05(statistically significant).
The mean time required for onset of motor block was less in group LS than 
group L and group LT. 
Table 6
Time of sensory block recovery
 Meantime  and  standard  deviation  of  sensory  block  recovery  in  group  L 
5.24+0.64.
Meantime and standard deviation of sensory block recovery in group L  
 5.16+0.9 and p value is >0.05(statistically not significant)
Meantime and standard deviation of sensory block recovery in group LS 
5.08+0.5 and p value is >0.05(statistically not significant)
Meantime required for sensory block recovery in group LS and group LT 
was  not  significantly  different  for  group  L.  These  finding  showed  that 
addition of sufentanil or tramadol to lignocaine did not affect the sensory 
block recovery time.
Table 7
Time of motor block recovery
Meantime and standard deviation of motor block recovery in group L   
6.48+1.09
Meantime and standard deviation of sensory block recovery in group LT   
6.24+1.29 and p value is >0.05(statistically not significant)
Meantime and standard deviation of sensory block recovery in group LS 
6.20+1.15 and p value is >0.05(statistically not significant)
Meantime required for motor block recovery in group LS and group LT was 
not significantly different for group L. These finding showed that addition of 
sufentanil or tramadol to lignocaine did not affect the motor block recovery 
time.
Table 8
Mean time of postoperative analgesia
Group Mean time and SD of post operative analgesia
Group L
Group LT
Group LS
191.4+26.96
203.8+19.69
223.2+14.19
Meantime of post operative analgesia in group LS was more than group L 
and group LT. p value for group LS is <0.05(statistically significant)
and for group LT is >0.05(statistically not significant)
Table 9 
Mean dose requirement of analgesic post operatively
Group Mean dose of post operating
          Group L
Group LT
Group LS
120+37.49
105+38.1
90+30.75
Mean dose requirement of analgesic post operatively in group LS was less 
than group LS group LT. p value for group LS is <0.05(statistically 
significant) and for group LT is >0.05(statistically not significant)
Table 10
VAS SCORE DURING INTRAOPERATIVE PERIOD 
(MEDIAN)
There was no difference in VAS score for tourniquet pain before and 
after tourniquet inflation and at 5, 10, 15 minutes. But at 20 and 40 minutes 
there  was  a  significant  increase  in  tourniquet  pain  in  group  L  when 
compared to other groups.  
Table 11
Total duration of surgery
Total duration 
of surgery in 
minutes
Group L Group LT Group LS
< 40
41-50
51-60
>60
3
8
11
3
2
7
15
1
3
6
15
1
Meantime of surgery in group L   : 50.8
 
Meantime of surgery in group LT: 53.4
Meantime of surgery in group L S: 53.2
Table 12
Total duration tourniquet
Total duration of 
tourniquet in 
minutes
Group L Group LT Group LS
< 50
51-60
61-70
> 70
3
8
11
3
2
7
15
1
3
6
15
1
 
Meantime of tourniquet in group L:     60.6
Meantime of tourniquet in group L T:  63.4
 
Meantime of tourniquet in group L S:  63.4
Table 13
SIDE EFFECTS
Side effects Group L Group LT Group LS
TINNITUS
LIGHT HEADEDNESS
PERIORAL NUMBNESS
VOMITING 
NAUSEA
SOMNOLENCE
VERTIGO
SKIN RASHES
ARRHYTHMIAS
CONVULSIONS
0
1
1
1
0
0
0
0
0
0
0
0
1
1
0
0
0
1
0
0
0
0
0
1
0
4
0
0
0
0
In general there were no significant side effects encountered. In group 
LT there was a case reported skin rash, which was disappeared after two 
hours  post  operatively.  In  group  LS  there  was  four  cases  reported 
somnolence post operatively.
REVIEW OF LITERATURE
Mona Raafat Fahim et al (2005)
This study was designed to evaluate the effect sufentanil, tramadol or 
dexmedetomidine added to lignocaine for intravenous regional anaesthesia. 
They investigated the onset and duration of sensory and motor block, the 
quality  of  anesthesia,  intra  operative  and  postoperative  hemodynamic 
changes, intra operative and postoperative pain and sedation. 
They  concluded  that  addition  of  sufentanil,  tramadol  or 
dexmedetomidine  shortened  the  onset  of  the  sensory  block,  delayed  the 
onset  of  tourniquet  pain  and reduced  the  intra  operative  consumption  of 
opioid and dexmedetomidine being the best of the three drugs.
Goel Daftray Pantavaidya et al. (2002)
In  their  double  blind  randomized  prospective  study  of  60  adult 
patients  under going upper limb surgeries,  they used 30 mg ketorolac or 
50mg tramadol with 40ml of 0.5% lignocaine. Intraoperatively the patient’s 
pain  score  was  evaluated  using  visual  analogue  scale.  All  patients  were 
compared for the time to first analgesic dose post operatively. Tramadol was 
found to be significantly better compared to ketorolac with respect to time to 
first analgesic and total analgesic used in twenty four hours.  
Hoffman el at (1997)
They studied the addition of  25µg sufentanil with 1% prilocaine for 
upper  limb surgeries  in  15 patients.  They concluded that  the addition of 
25µg of sufentanil shortened the onset of sensory block compared to control 
by  three  minutes.  No  post  operative  benefits  were  demonstrated.  Light 
headedness after tourniquet deflation was reported in 8/15 but this was not 
analyzed statistically. 
Acalovschi et al (2001)
This study looked at  the intra operative effects  of  adding tramadol 
100mg with 40ml 0.5% lignocaine. The resultant sensory block (pinprick, 
touch and temperature) was faster in onset  compared to plain lignocaine. 
However, only touch sensation was slower to recover. Onset and recovery of 
motor  blocked  was  not  affected.  Skin  rash  below  the  tourniquet  that 
disappeared within one hour of deflation was the only significant side effect. 
When  tramadol  was  added  to  lignocaine  possible  benefit  in  terms  of 
tourniquet pain and postoperative course were not investigated.
Lai, chang, Yeh et al (1993)
They studied the site of action of lignocaine in intravenous regional 
anaesthesia.  The  study  was  conducted  in  15  patients  receiving  surgical 
operation on the hands and forearms. Two tourniquets were secured, one on 
the arm and another on forearm. Two different concentrations (0.5% and 
2%) of lignocaine injected in the intercuff area through 22G cannula and 
analgesia was observed. The results showed that 0.5% lignocaine produced 
analgesia  in  intercuff  area  only,  and  in  patients  received  2% lignocaine 
experienced analgesia rapidly on the intercuff area and also slowly on the 
forearm and hand. The anaesthesia developed from fingertips upward. Based 
on this evidence they concluded that the principal site of action of lignocaine 
in  intravenous  regional  anesthesia  depends  on  concentration.  The  lower 
concentration  acts  on  sensory  nerve  endings,  where  as  the  higher 
concentration acts on both nerves and nerve endings. 
Sulchani, Garcia, Munhall et al. (1989)
In this study the studied cyclic deflation and reinflation of tourniquet 
at  the  termination  of  intravenous  regional  anaesthesia  and  safety  of  the 
technique by minimizing the peak blood level of local anaesthetic and the 
time to reach this peak level. They studied in three groups. In the first group 
the tourniquet was simply deflated and not reinflated. In the second group 
the tourniquet was deflated for three times with variable time of deflation 
( 0, 10 and 30 seconds ) separated by 1minute period of reinflation, and in 
the third group the tourniquet was deflated for 3 times in fixed period of 
deflation ( 10 seconds ) separated by 1 minute period of reinflation. The 
results  obtained  indicate  that  cycling  techniques  did  not  appear  to 
significantly  reduce  peak  plasma  concentration  but  cycling  techniques 
significantly prolong the time to reach peak plasma concentration. Of the 
two cycling methods, the 10 second deflation interval technique appeared to 
be superior both clinically and pharmacologically.
Stene et al (1995)
In  this  study  they  studied  presence  of  peripheral  opioid  receptors. 
They concluded that small, systemically inactive doses of exogenous opioids 
administered in  the  vicinity  of  peripheral-nerve  terminals  have  beneficial 
analgesic effects. Opioid receptors are present on those nerve terminals, and 
endogenous opioid peptides are detectable in inflamed tissue in both animals 
and humans. Opioid receptors located on peripheral sensory nerves can be 
activated by these opioids and mediate the endogenous inhibition of pain. 
Thus, peripheral opioid receptors can modulate sensory-nerve impulses in a 
way similar to the action of presynaptic opioid receptors in the spinal cord. 
The  peripheral  action  of  opioids  provides  a  new approach  to pain 
management.  Peripherally  acting  opioids  would  allow  analgesia without 
central  side  effects,  such  as  dysphoria,  respiratory depression,  sedation, 
nausea, or addiction, and without the side effects either of nonsteroidal anti-
inflammatory  drugs  (e.g., renal  toxicity  and gastric  bleeding)  or  of  local 
anaesthetic drugs  (motor-  and  autonomic-nerve  blockade).  Whether 
tolerance to the analgesic effects of peripherally active opioids develops is 
not known. The fact that peripheral opioid actions are particularly prominent 
in inflamed tissue may be clinically advantageous, considering that  many 
painful conditions, sub acute or chronic, are associated with inflammation 
(for example, trauma, postoperative pain, pain due to cancer, and arthritis). 
In addition to their immunologic functions,  immune cells are involved in 
intrinsic mechanisms of pain inhibition. This involvement may provide new 
insights into the pain associated with a compromised immune system, as in 
patients  with  the  acquired  immunodeficiency  syndrome, cancer,  or 
autoimmune disorders. 
DISCUSSION
A better  approach for  avoidance  of  general  anaesthesia  is  regional 
anaesthesia by the use of local anaesthetics. One of such regional anaesthetic 
technique used in upper limb surgeries is intravenous regional anaesthesia.
This  technique  was  chosen  for  this  study  with  consideration  of 
following merits and demerits.
Merits:
1. Simple technique – Insertion of IV cannula is the only necessary 
skill required.
2. Reliable and effective when properly used.
3. Rapid onset of action.
4. Rapid and prompt recovery after tourniquet release.
5. Good analgesia and adequate muscle relaxation 
6. Provides blood less operative field.
7. Widely applicable to patients of different ages and physical status 
for operation of targeting duration.   
Demerits: 
1. Duration of analgesia is limited by the duration of cuff inflation.
2. Restricted only to extremity surgeries  especially  distal  to  elbow 
and distal to knee in lower limb.
3. Tourniquet is essential prerequisite of the technique.
4. Analgesia cannot be extended to the postoperative period.
5. Tourniquet pain is common.
6. Local  anaesthetic  toxic  reactions  like  convulsions,  coma,  cardio 
respiratory  depression  and  cardiac  arrest  has  been  reported 
following accidental deflation of tourniquet.
Contraindications: 
1. Patient refusal
2. Absence of resuscitative equipments and drugs.
3. Allergy to local anesthetics 
4. Infection and cellulites in the limb to be blocked
5. Conditions precluding use of tourniquet like
a. Scleroderma
b. Hemolytic diseases such as sickle cell anemia, thalasemia
c. Raynaud’s disease
d. Malignancy
6. Lengthy cases 
7. Patients with seizure disorders or with cardiac disorders.
Intravenous  regional  anaesthesia  is  an  ideal  technique  for  short 
operative  procedures  on  the  extremities.  Intravenous  regional  anaesthesia 
has been limited by chance of local anaesthetic toxicity, slow onset, poor 
muscle relaxation, tourniquet pain and minimal post operative pain relief. To 
improve  the  quality  of  intravenous  regional  anaesthesia,  the  addition  of 
various opioids to local anaesthetics has been tried.
Pitkanen et al (1992) studied the effect of fentanyl 100 µg with 0.5% 
prilocaine in intravenous regional anaesthesia for upper limb surgeries. They 
concluded that the sensory block onset was faster with fentanyl and recovery 
time was equal, they reported side effects like light-headedness, dizziness 
and nausea. 
Arthur et al (1992) studied sensory block onset and recovery, motor 
block  onset  with  addition  of  100  µg  fentanyl  with  0.25% lignocaine  in 
intravenous  regional  anaesthesia.  They  concluded  that  the  sensory  block 
onset  was  faster.  Sensory  recovery  and  motor  block  recovery  were  not 
affected by addition of fentanyl. There were no side effects reported.  
Hoffman et al (1997) studied the addition of sufentanil 25  µg with 
prilocaine  in  intravenous  regional  anaesthesia.  They  reported  that  the 
addition  of  sufentanil  shortened  the  onset  of  sensory  block  compared to 
control  by  about  three  minutes.  No  postoperative  benefits  were 
demonstrated.
Acalovschi et al (2001) looked at the intra operative effects of adding 
tramadol 100 mg with 0.5% lignocaine.  The resultant  sensory block was 
faster in onset compared to plain lignocaine. Onset and recovery of motor 
block was not affected.
In  our  study  it  was  planned  to  compare  efficacy  of  sufentanil, 
tramadol added with 0.5% lignocaine in intravenous regional anaesthesia for 
hand surgeries,  and observed the sensory block onset time, sensory block 
recovery time motor block onset time, motor block recovery time, tourniquet 
pain,  post  operative  analgesia  time  and  dose  requirement  of  analgesic 
(diclofenac) post operatively.
In our study there was no significant difference between groups for 
blood pressure, pulse rate during preoperative and intraoperative time.    
In our study the sensory block onset time was more rapid in group LS 
when compared with group L and group LT. This finding was coincided 
with the results found by  Hoffman et.al. The sensory block onset time in 
group LT was rapid when compared to group L and the same finding was 
made by Alayurt et al. But the sensory block onset time was more in group 
LT than group LS. These findings showed that addition of sufentanil with 
lignocaine shortened the onset of sensory block. 
The  motor  block  onset  time  was  more  rapid  in  group  LS  when 
compared to group L and group LT. This finding was coincided with the 
results found by Alayurt et al. The motor block onset time was shorter in 
group LT when compared to group L.  But when compared to group LS. 
motor block onset time was longer in group LT.These findings showed that 
addition of sufentanil with lignocaine shortened the onset of motor block. 
In  our  study,  the sensory block recovery time was not  different  in 
group LS and group L. This finding coincided with the results derived by 
Alayurt et al. In group LT the sensory block recovery time was not different 
from  group  L  and  this  finding  correlated  with  the  results  found  by 
Acalovschi et al. These finding showed that both sufentanil and tramadol 
did not affect the sensory block recovery time.
The motor block recovery time in group LS was not different from 
group L. This finding coincided with the findings found by Hoffman et al. 
In group LT the motor block recovery time was not different from group L. 
This finding coincided with results found by Acalovschi et al. These results 
showed that  both sufentanil  and tramadol  did not  affect  the motor block 
recovery time.
In our study, there was no difference between groups in scores for 
tourniquet pain after tourniquet inflation, and at 5, 10, 15 minutes. But at 20 
and 40 minutes there was significant increase in tourniquet pain in-group L 
when  compared  with  other  groups.  This  finding  was  correlated  with  the 
findings made by  Mona Raafat Fahim et al. These findings showed that 
the ability of sufentanil and tramadol in reducing tourniquet pain.
In our study, the duration of postoperative analgesia was longer in 
group LS than group L and group LT. This finding correlated with results of 
Mona Raafat  Fahim et  al.  In  group LT,  the duration of  post  operative 
analgesia was longer than group L but shorter than group LS. These findings 
indicated  that  the  addition  of  sufentanil  with  lignocaine  prolonged  the 
duration of postoperative analgesia.
In our study, the amount of postoperative analgesic (diclofenac in mg) 
was less in group LS than group L and group LT. These finding coincided 
with the results of Mona Raafat Fahim et al. The amount of post operative 
analgesic in group LT was less when compared with group L but more when 
compared  with  group  LS.  These  findings  showed  that  the  addition  of 
sufentanil  with  lignocaine  reduces  the  amount  of  postoperative  analgesic 
post operatively.
In our study, it was found that the addition of sufentanil and tramadol 
to lignocaine in intravenous regional anaesthesia shortened the onset time of 
sensory block, motor block, delayed the onset of tourniquet pain, lengthened 
post operative pain relief and reduced amount of post operative analgesic 
with  out  altering  sensory  block  and  motor  block  recovery  time.  In  this 
regard,  sufentanil  was  more  effective  in  reducing  onset  time  of  sensory 
block, motor block, lengthened postoperative pain relief and reduced amount 
of postoperative analgesic than tramadol.
CONCLUSION
 We conclude that addition of sufentanil and tramadol to lignocaine in 
intravenous regional anaesthesia shortened the onset time of sensory block, 
motor block, delayed the onset of tourniquet pain, lengthened post operative 
pain relief and reduced amount of post operative analgesic drug with out 
altering  sensory  block  and  motor  block  recovery  time.  In  this  regard, 
sufentanil was more effective than tramadol.
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                                                        PROFORMA
INTRAVENOUS REGIONAL ANAESTHESIA USING LIGNOCAINE 
,SUFENTANIL AND TRAMADOL
NAME: AGE: IPNO:
SEX: WEIGHT:
DIAGNOSIS: PROCEDURE:
HISTORY:
STARVATION:
PRE OPERATIVE EXAMINATION:
PULSE RATE: CVS:
BLOOD PRESSURE: RS:
TEMPERATURE: CNS:
ABDOMEN:
INVESTIGATIONS:
Hb: BLOOD SUGAR: UREA: CREATININE:
ECG: X RAY CHEST: OTHERS:
AIRWAY:
ASA PHYSICAL STATUS:
PATIENT GROUP: LIGNOCAINE / LIGNOCAINE WITH SUFENTANIL/
LIGNOCAINE WITH TRAMADOL
TOURNIQUET:
INFLATION TIME: DEFLATION TIME:
SENSORY BLOCK ONSET TIME: (MIN)
MOTOR BLOCK ONSET: (MIN) 
INTRA OP HEMODYNAMICS
1 MIN 5MIN 10MIN 20MIN 40MIN 60MIN 75MIN 90MIN
PR
BP
 INTRA OP TOURNIQUET PAIN: AT 5 MIN     10MIN    20 MIN     40 MIN
(VAS)
 SUPPLEMENTATION OF GA DUE TO T.PAIN:  YES / NO
TOTAL DURATION OF TOURNIQUET: (MIN) 
TOTAL DURATION OF SURGERY: (MIN)  
SENSORY BLOCK RECOVERY TIME: (MIN) 
MOTOR BLOCK RECOVERYTIME: (MIN) 
TOTAL DURATION OF POST OP ANALGESIA: (MIN)
POST OP ANALGESIA WITH RESCUE DRUG GIVEN: YES / NO
TOTAL DOSE OF ANALGESIC GIVEN: (mgs)
ADVERSE EFFECTS:
TINNITUS : YES / NO
LIGHT HEADEDNESS : YES / NO
PERIORAL NUMBNESS : YES / NO
VOMITING : YES / NO
NAUSEA : YES / NO
SOMNOLENCE : YES / NO
VERTIGO : YES / NO
SKIN RASHES : YES / NO
ARRHYTHMIAS : YES / NO
CONVULSIONS : YES / NO
